Introduction {#Sec1}
============

The prevalence of diabetes mellitus has been increasing during the past few decades with rapid rises in incidence in the 1990s and early 2000s \[[@CR1], [@CR2]\]. Type 2 diabetes is now more frequently diagnosed in young adults and adolescents \[[@CR3]--[@CR5]\]. The obvious reason for this is increasing obesity among young people. In the 1990s, obesity increased by 70% in people aged 18--29 years in the USA and, in the same decade, type 2 diabetes also increased by 70% in people aged 30--39 years \[[@CR2], [@CR6]\]. Consequently, in recent years, type 2 diabetes has sometimes been categorised as early-onset diabetes, i.e. people diagnosed before the age of 45, and later-onset (or usual-onset), i.e. people diagnosed ≥45 years of age \[[@CR7]\].

Cardiovascular disease (CVD) is a major cause of mortality in individuals with type 2 diabetes \[[@CR8], [@CR9]\]. From a cardiovascular perspective, early-onset type 2 diabetes appears to be more aggressive than later-onset disease. For example, when younger people are diagnosed with type 2 diabetes they often already have several risk factors for developing CVD \[[@CR10]--[@CR12]\]. Our research group recently confirmed that younger age at type 2 diabetes diagnosis and poor glycaemic control were individually correlated with excess risk of death from any cause and from CVD \[[@CR13]\]. Furthermore, others have shown that early-onset type 2 diabetes is more strongly pathogenic than type 1 diabetes \[[@CR14]\]. However, the reasons behind the higher risk of complications in early-onset type 2 diabetes are not fully understood.

Whilst there are some data to suggest that obesity and differential changes in blood glucose may be operating in early-onset type 2 diabetes, a comprehensive study examining major CVD risk factors according to age at diagnosis, as well as examining subsequent trends in risk factor control, is lacking. Therefore, the aims of this study were to evaluate, in relation to age at diagnosis: (1) clinical characteristics at diagnosis; (2) trajectories (time trends) in CVD risk factors over the initial years following type 2 diabetes diagnosis; and (3) whether any apparent differences were inter-related (e.g. BMI vs lipids) or could be easily explained by differential treatments (e.g. statins and glucose-lowering drugs).

Methods {#Sec2}
=======

The primary aim of this observational study was to describe how CVD risk factors change over time from diagnosis of type 2 diabetes depending on age at diagnosis in using data from the Swedish National Diabetes Register (NDR). The NDR was launched in 1996 as a nationwide clinical quality register that aims to support and monitor improvements in the quality of diabetes care. It now contains clinical data on about 90% of individuals aged ≥18 years with diabetes (type 1 and type 2) in Sweden. Before inclusion into the NDR informed consent has to be provided by each participant \[[@CR15], [@CR16]\]. Ethical approval to conduct this study was acquired from the Regional Ethical Review Board in Gothenburg, Sweden.

Study population {#FPar1}
----------------

Individuals with newly diagnosed type 2 diabetes who had at least one listing in the NDR between 1 January 2002 and 31 December 2012 were identified. Type 2 diabetes was defined on the basis of epidemiological data: individuals receiving dietary treatment only, oral glucose-lowering agents only, or those diagnosed at ≥40 years of age receiving insulin therapy or insulin and oral glucose-lowering agents. In Sweden, the WHO diagnostic criteria are used to diagnose diabetes \[[@CR17]\]. All individuals who did not have information on age at diagnosis of diabetes were excluded. We assessed potential misclassification bias by comparing the concordance between the epidemiological definitions of type 2 diabetes with the clinician's classification of diabetes type (which is also available in the NDR); we confirmed that 97% of our cohort were also classified as type 2 diabetes by their clinician.

Newly diagnosed individuals in each age category (age at type 2 diabetes diagnosis) were followed until death or end of follow-up on 31 December 2012. The median follow-up was 2.22 years (interquartile range, 0.80--4.31 years; maximum, 10.9 years; mean follow-up was 2.8 years). Thus, we studied individuals who were enrolled in the NDR in the same year that they were diagnosed and we followed them for up to 10 years. Reporting into the NDR is performed approximately annually, which results in multiple measurements being available for each participant. Our final cohort consisted of 100,606 individuals contributing 679,420 observations. We categorised the cohort into the following four age groups (age at type 2 diabetes diagnosis was equal to actual age owing to the inclusion criteria): 18--44 years, 45--59 years, 60--74 years and ≥75 years.

Details on variables {#d29e445}
--------------------

Glycaemic control was estimated based on HbA~1c~ measurements, which were calibrated nationwide with the HPLC Mono-S method and converted into mmol/mol according to the International Federation of Clinical Chemistry \[[@CR18]\]. Systolic BP (SBP) and diastolic BP (DBP) were measured in mmHg. BMI was calculated as weight (kg) divided by the height squared (m^2^). Blood lipid profile was estimated based on LDL-cholesterol, HDL-cholesterol, triacylglycerols and total cholesterol measurements, all measured in mmol/l. Serum creatinine was measured in μmol/l and eGFR was carried out by the Modification of Diet in Renal Disease (MDRD) study equation.

Microalbuminuria was defined as two positive results for three samples obtained within 1 year of each other, with an albumin/creatinine ratio of 3--30 mg/mmol or a urinary albumin clearance of 20--200 μg/min. All variables were assessed from 2002 to 2012. Initial medication data were obtained within 3 months of diagnosis.

Statistical analysis {#FPar2}
--------------------

Continuous dependent variables (e.g. SBP) were analysed using a mixed-effects model that incorporated a random participant effect, fixed effects of age group, time, and a time by age group interaction where time was a categorical variable. This allowed for separate estimates of time trends for each age group. HbA~1c~ observations were analysed starting 1 year after diagnosis to avoid the rapid drop in HbA~1c~ commonly seen during the first year. The models contained adjustment factors, such as sex, BMI, smoking and concomitant treatment subject to convergence, as well as, where relevant, socioeconomic (marital status and education) measures and country of birth (categorised as in Table [1](#Tab1){ref-type="table"}). Complete information on other adjustment variables is available in the ESM Table [1](#MOESM1){ref-type="media"}. The mixed-repeated-measures model handles missing data under the assumption of missing at random without relying on crude imputation techniques, such as last value carried forward, and is therefore less prone to bias.Table 1.Baseline descriptive statistics stratified by age groups.VariableMissing data, *n* (%)Overall18--44 years of age45--59 years of age60--74 years of age≥75 years of age*n*100,606864230,90745,26915,788Follow-up time (years)2.8 (2.5)2.5 (2.5)2.9 (2.6)2.9 (2.5)2.7 (2.3)Sex, women0 (0.0)44,925 (44.7)3442 (39.8)11,695 (37.8)19,865 (43.9)9923 (62.9)Age (years)0 (0.0)62.0 (12.3)38.3 (5.6)53.1 (4.2)66.2 (4.1)80.4 (4.4)HbA~1c~8208 (8.2)  mmol/mol49.2 (11.0)51.5 (14.6)50.4 (12.3)48.2 (9.7)48.5 (9.4)  %6.7 (1.0)6.9 (1.3)6.8 (1.1)6.6 (0.9)6.6 (0.9)  \>53 mmol/mol16, 462 (17.6)1782 (32.4)6001 (28.0)6360 (20.0)2319 (20.8)BMI (kg/m^2^)25,701 (25.5)30.6 (5.7)33.4 (7.3)31.5 (5.8)30.2 (5.2)28.3 (4.7)BMI \>30 kg/m^2^25,701 (25.5)36,437 (48.6)4131 (65.3)12,964 (55.7)15,753 (46.3)3589 (31.9)SBP (mmHg)18,480 (18.4)137.3 (17.3)128.4 (15.3)134.9 (16.5)139.1 (16.9)141.6 (18.3)Systolic hypertension (\>140 mmHg)18,480 (18.4)26,766 (32.6)982 (14.8)6737 (26.9)13,502 (36.2)5545 (42.0)DBP (mmHg)18,480 (18.4)79.7 (10.0)80.5 (10.5)82.0 (9.9)79.4 (9.6)75.6 (9.8)Diastolic hypertension (\>90 mmHg)18,480 (18.4)7918 (9.6)809 (12.2)3494 (14.0)3109 (8.3)506 (3.8)Total cholesterol (mmol/l)33,648 (33.4)5.3 (1.2)5.3 (1.2)5.4 (1.2)5.2 (1.1)5.1 (1.1)Hypercholesterolaemia (\>6.2 mmol/l)33,648 (33.4)12,208 (18.2)939 (17.7)4401 (20.8)5519 (17.6)1349 (14.8)LDL-cholesterol (mmol/l)42,691 (42.4)3.1 (1.0)3.2 (1.0)3.2 (1.0)3.1 (1.0)3.0 (1.0)HDL-cholesterol (mmol/l)40,893 (40.6)1.2 (0.4)1.1 (0.3)1.2 (0.4)1.3 (0.4)1.3 (0.4)Triacylglycerol (mmol/l)40,037 (39.8)2.0 (1.4)2.4 (1.8)2.2 (1.6)1.9 (1.2)1.7 (0.9)Microalbuminuria^a^51,166 (50.9)6110 (12.4)492 (11.6)1820 (11.6)2732 (12.2)1066 (15.1)eGFR (ml/min)22,951 (22.8)84.8 (25.2)105.8 (26.9)93.5 (25.3)81.8 (21.1)67.0 (19.9)Smoker22,205 (22.1)14,257 (18.2)1540 (24.1)6117 (25.2)5875 (16.5)725 (5.9)Medication use^b^  Antihypertensive agents7845 (7.8)57,686 (62.2)1801 (23.1)14,499 (51.2)29,630 (70.5)11,756 (80.4)  Statins7927 (7.9)35,582 (38.4)1285 (16.3)9575 (33.6)19,029 (45.4)5693 (39.5)  No medication0 (0.0)52,491 (52.2)3824 (44.2)14,094 (45.6)24,533 (54.2)10,040 (63.6)  Oral glucose-lowering agents0 (0.0)38,582 (38.3)3973 (46.0)13,197 (42.7)16,894 (37.3)4518 (28.6)  Insulin0 (0.0)5589 (5.6)525 (6.1)2031 (6.6)2194 (4.8)839 (5.3)  Insulin + oral glucose-lowering agents0 (0.0)3944 (3.9)320 (3.7)1585 (5.1)1648 (3.6)391 (2.5)Marital status448 (0.4)  Single18,283 (18.3)4099 (47.5)8155 (26.5)5212 (11.6)817 (5.2)  Married53,276 (53.2)3587 (41.6)15,933 (51.7)26,678 (59.2)7078 (45.3)  Separated17,917 (17.9)910 (10.5)6194 (20.1)9042 (20.1)1771 (11.3)  Widowed10,682 (10.7)35 (0.4)549 (1.8)4152 (9.2)5946 (38.1)Country of birth0 (0.0)  Sweden81,545 (81.1)5839 (67.6)23,267 (75.3)38,412 (84.9)14,027 (88.8)  Europe (excl. Sweden)10,612 (10.5)710 (8.2)3441 (11.1)5047 (11.1)1414 (9.0)  Rest of world8449 (8.4)2093 (24.2)4199 (13.6)1810 (4.0)347 (2.2)Education1881 (1.9)  Elementary school36,743 (37.2)1881 (22.2)8099 (26.5)17,687 (39.8)9076 (59.6)  College level44,029 (44.6)4719 (55.8)15,862 (51.9)18,939 (42.6)4509 (29.6)  Upper/secondary school17,953 (18.2)1858 (22.0)6617 (21.6)7827 (17.6)1651 (10.8)All data are based on the first observation after diagnosis, except for HbA~1c~ where the first observation 1 year after diagnosis was usedAll continuous variables are represented as mean (SD). Dichotomous variables are represented as number of individuals (%).^a^Microalbuminuria was defined as two positive results for three samples obtained within 1 year of each other, with an albumin/creatinine ratio of 3--30 mg/mmol or a urinary albumin clearance of 20--200 μg/min^b^Initial medication data were obtained within 3 months of diagnosis

The graphical representation of the data is based on estimated and observed yearly averages with 95% CI for up to 8 years after diagnosis. Sensitivity analyses, adjusted for confounders, were conducted for individuals with at least 5 years of follow-up (ESM Fig. [2](#MOESM1){ref-type="media"}a--e), which included adjustments for the confounders shown in ESM Table [1](#MOESM1){ref-type="media"}. Further sensitivity analyses were additionally adjusted for marital status, education and country of birth.

A *p* value \<0.05 was considered to be statistically significant and, since no adjustment for multiple comparisons has been made, the interpretations should focus on the overall patterns rather than the outcomes of single hypothesis tests. All statistical analyses were conducted with SAS (version 9.4; [www.sas.com/en_gb/software/sas9.html](http://www.sas.com/en_gb/software/sas9.html), accessed 10 November 2017) and R (version 3.2.3) ([https://www.rstudio.com/products/rstudio/download/](https://www.rstudio.com/products/rstudio/download); <https://cran.hafro.is/>; both accessed 10 November 2017).

Results {#Sec3}
=======

Baseline characteristics and risk factor differences {#FPar3}
----------------------------------------------------

Table [1](#Tab1){ref-type="table"} shows baseline characteristics in the overall cohort stratified by age group. Baseline was defined as the participant's first observation in the NDR at year of diagnosis. Women represented 44.7% of the total cohort. The mean age (years) in each age group was 38.3, 53.1, 66.2 and 80.4. At diagnosis, the youngest group contained proportionately more men, had a higher mean BMI by about 5 kg/m^2^ and a higher mean HbA~1c~ of \~3 mmol/mol (0.27%) compared with the oldest group. The youngest group also had the highest triacylglycerol and the lowest HDL-cholesterol levels of all the groups. However, this group had the lowest SBP and one of the highest DBP compared with the other age groups. In terms of treatments, statin use was lowest in youngest age group, being almost three times lower than rates of use in the 60--74 years age group. In contrast, oral glucose-lowering agent use was higher in the youngest group at 46% vs 29% in the oldest group. In addition, antihypertensive agent use was considerably lower in the youngest group at 23% vs 80% in the oldest group. Considerably more of the younger cohort were from countries outside Europe. Men had higher HbA~1c~ levels at diagnosis compared with women, but women had higher BMI (ESM Table [2](#MOESM1){ref-type="media"}).

Risk factor trajectories {#FPar4}
------------------------

The trajectories of cardiometabolic risk factors over time by age at type 2 diabetes diagnosis are presented in Fig. [1](#Fig1){ref-type="fig"}. The significantly (*p* \< 0.05) higher BMI level observed in the youngest age group at diagnosis was sustained over time relative to the other groups (Fig. [1](#Fig1){ref-type="fig"}a). A widening and significant (*p* \< 0.05) difference in HbA~1c~ was observed over time, with a difference of \~5 mmol/mol (0.45%) at 8 years between the youngest vs two oldest age groups (Fig. [1](#Fig1){ref-type="fig"}b).Fig. 1Yearly averages (95% CI) stratified by age group for (**a**) BMI, (**b**) HbA~1c~, (**c**) triacylglycerol, (**d**) HDL-cholesterol and (**e**) LDL-cholesterol. White circles, 18--44 years old; plus sign (+), 45--59 years old; crosses (×), 60--74 years old; white triangles, ≥75 years old. All analyses, *p* \< 0.05 where 95% CI do not overlap

Lipid levels remained significantly (*p* \< 0.05) different between age groups, with the youngest group showing continually higher triacylglycerol levels (by \~0.5--0.6 mmol/l) compared with the two oldest age groups, and lower HDL-cholesterol levels compared with all other age groups (although this latter difference narrowed over time) (Fig. [1](#Fig1){ref-type="fig"}c,d). The differences in LDL-cholesterol levels between age groups widened over time; even though levels in all groups declined this widening probably reflects more frequent use of statins in the older age groups (Fig. [1](#Fig1){ref-type="fig"}e).

In summary, individuals that developed type 2 diabetes at a younger age had greater aggregated exposure (i.e. AUC) to higher BMI, higher blood glucose levels and abnormal lipids compared with those who developed diabetes at an older age.

Other risk factors (including BP, renal function, total cholesterol and albuminuria) also changed over time (ESM Fig. [1](#MOESM1){ref-type="media"}a--e), but most were as expected. The use of statins and antihypertensive agents was lowest in the youngest age group at diagnosis and this was sustained, at least in the early years following diagnosis (ESM Fig. [1](#MOESM1){ref-type="media"}f,g). Finally, number of current smokers was highest in the youngest age group and this did not change over time (ESM Fig. [1](#MOESM1){ref-type="media"}h).

Sensitivity analyses in individuals with at least 5 years follow-up {#FPar5}
-------------------------------------------------------------------

When we restricted analyses to only include individuals with at least 5 years follow-up and adjusted for key confounders for each of the main risk factors as depicted in ESM Table [1](#MOESM1){ref-type="media"}, the findings were broadly similar to those reported for the entire cohort with unadjusted analyses (see ESM Fig. [2](#MOESM1){ref-type="media"}a--e). For example, the trajectory of blood glucose levels after the first year was significantly (*p* \< 0.05) greater in the youngest group relative to the older groups, leading to the highest blood glucose levels observed in this group at year 6, despite adjustment for diabetes medication and BMI. Likewise, differences in lipid abnormalities persisted despite adjustment for sex, BMI and lipid-lowering therapy. Further analyses adjusting for marital status, education and country of birth did not materially change the pattern of results (ESM Fig. [3](#MOESM1){ref-type="media"}a--e).

Discussion {#Sec4}
==========

To the best of our knowledge, this study of 100,606 individuals with newly diagnosed type 2 diabetes is the largest and perhaps the first to compare in detail trajectories on several cardiometabolic risk factors between individuals with type 2 diabetes grouped according to age of diagnosis in a European (white) population, complementing and extending data from a recent study in China \[[@CR19]\]. The results from our study show that age at diagnosis of type 2 diabetes is an important aspect of risk factor control with regard to adiposity, blood glucose and lipid levels; these factors were all worse in individuals diagnosed at a younger age and throughout the early years following diagnosis, during which the use of glucose-lowering medication was higher in this group relative to older individuals. Moreover, such differences appear not to be accounted for by obvious confounders including differential drug therapy rates, sex, smoking and, where relevant, BMI differences by age group. The results were also maintained when we adjusted for socioeconomic variables and, in particular, country of birth. Therefore, our findings support the notion that early-onset type 2 diabetes may be a more pathogenic condition per se than later-onset type 2 diabetes, helping to explain the observation of greater life-years lost when diabetes is diagnosed at a younger age, as recently reported \[[@CR20], [@CR21]\].

Our data on the relationship between age at diagnosis and cardiometabolic risk factors meaningfully extend previous studies \[[@CR22], [@CR23]\] as it is contemporary and multiple-fold larger in terms of size. Our results also hold potential clinical relevance. With respect to hyperglycaemia, despite a higher rate of glucose-lowering agent use in younger (i.e. ≤45 years of age) compared with older individuals (Table [1](#Tab1){ref-type="table"}), younger individuals had higher HbA~1c~ levels and worse trajectories over time, so their aggregated exposure to hyperglycaemia is worse from the point of diagnosis (and potentially prior to diagnosis if diagnosed later). Therefore, total exposure to hyperglycaemia is clearly higher in younger individuals and, since hyperglycaemia is a strong and independent predictor for microvascular complications and has long-term consequences for CVD in individuals with type 2 diabetes \[[@CR13], [@CR24], [@CR25]\], the risk of complications driven in part by hyperglycaemia should be higher in this group. Younger individuals may experience delayed diabetes diagnoses owing to a lower likelihood of opportunistic screening, but the poorer HbA~1c~ trajectories observed in this group despite similar or greater prescription rates for glucose-lowering medications suggest that undertreatment is unlikely to be the only reason for poor glycaemic control over time. Clearly, younger individuals are more frequently obese and their aggregated BMI over time is higher than in older individuals, which is possibly related to higher blood glucose levels over time; however, our sensitivity analyses suggest that blood glucose levels remain higher in the younger group even with adjustment for BMI (ESM Fig. [2](#MOESM1){ref-type="media"}b) and with adjustment for other factors including country of birth (ESM Fig. [3](#MOESM1){ref-type="media"}b). Of course, genetic factors may also be of greater importance for early-onset type 2 diabetes.

Dyslipidaemia, characterised by low HDL-cholesterol and elevated triacylglycerol levels, is a risk factor for CVD \[[@CR25]\]. In this study, younger individuals had lower HDL-cholesterol levels and higher triacylglycerol levels at diagnosis, in accordance with most previous studies \[[@CR22], [@CR23], [@CR26]\]; although Hillier et al, in a much smaller study, did not observe a difference in triacylglycerol levels between individuals with early-onset and later-onset type 2 diabetes \[[@CR23]\]. Whilst recent evidence indicates that higher triacylglycerol levels are causally linked to CVD \[[@CR27]\], other strong evidence indicates earlier hyperlipidaemia (as measured by either LDL-cholesterol or non-HDL-cholesterol---also higher in younger individuals in the present study) is associated with long-term harm \[[@CR28]\]. These collective findings broadly concur with greater obesity in younger individuals, although, once again, lipid differences remained with adjustments for BMI and lipid-lowering therapy use, which was lower in younger individuals in the early years following diagnosis and did not catch up with older groups for at least several years. This is notable since these younger individuals may have more to profit from preventive treatments, such as statins, in terms of gain of life-years free from CVD events \[[@CR29]\].

The poorer BMI, HbA~1c~ and lipid profiles observed in the younger individuals helps to explain why early-onset type 2 diabetes may confer a very high lifetime risk of CVD and premature death compared with later-onset disease \[[@CR13], [@CR19], [@CR30]\]. It is clear that the relative hazard of developing CVD is much greater in individuals with early-onset than later-onset disease, compared with age-matched individuals without diabetes \[[@CR7]\]. There have been increasing calls \[[@CR29], [@CR31]\] for earlier treatment of cardiometabolic risk factors for individuals with high lifetime risks of CVD to enhance survival benefits; younger individuals with type 2 diabetes fit these criteria well.

The strength of this study is that it is a nationwide study which included virtually all individuals with newly diagnosed type 2 diabetes in Sweden within the study period, and is thus representative of the general diabetes population. This is in contrast to smaller observational studies. However, we fully accept some, often inevitable, limitations. For example, our study only included Swedish nationals; whilst our results should be relevant to many high-income countries with high proportions of individuals of European descent, our work needs to be replicated in other ethnic groups. We also recognise that the overall mean length of follow-up was modest, but note that the same trends were observed in individuals who had at least 5 years of follow-up (ESM Fig. [2](#MOESM1){ref-type="media"}a--e). In addition, we cannot rule out the probability of missing BMI values from individuals with normal or close to normal BMI because these individuals may be less likely to have their BMI recorded, which could lead to a potential bias that would in fact underestimate, rather than overestimate, diagnosis-related BMI differentials by age, as well as changes in BMI over time. However, our BMI data fit well with recent findings in a Scottish diabetes dataset, lending some external validity \[[@CR32]\]. Finally, we acknowledge that higher HbA~1c~ levels at diagnosis in younger individuals is due, in part, to a greater delay in diagnosis compared with older individuals, perhaps because younger individuals are less likely to be captured by opportunistic screening. However, blood glucose levels remained higher over time, even after diagnosis, in those under 45 years of age (despite more of this group being on glucose-lowering therapy), potentially suggesting some innate contribution to higher risk blood glucose profiles.

In summary, individuals with early-onset type 2 diabetes are more obese at diagnosis and for several years afterwards, have higher blood glucose levels, and a faster deterioration of glycaemic control following 1 year of diagnosis compared with individuals diagnosed at an older age. They also have more atherogenic lipid profiles. Since such differences remained with adjustment for obvious confounders, including, where relevant, glucose- or lipid-lowering treatments and country of birth, our results support the notion that early-onset type 2 diabetes is a more pathogenic condition than later-onset disease. Irrespective of the reasons for worse adiposity, lipid and glycaemic risk factor profiles in the younger age group, these real-life data suggest a need for more aggressive management of type 2 diabetes in younger individuals to lessen life-years lost in this high-risk group.
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